Name
Diamyd Medical AB
What We Do
Diamyd Medical is a Swedish biotech company developing precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA. Diamyd® (rhGAD65) is an investigational antigen-specific immunotherapy aiming to preserve the body’s own insulin production specifically for individuals carrying the HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. and Fast Track Designation by the FDA for the treatment of Stage 3 (clinically diagnosed) as well as for the treatment of Stage 1 and 2 (pre-symptomatic) T1D. Diamyd® is currently being evaluated in the Breakthrough T1D-partnered Phase III Stage 3 trial DIAGNODE-3 (www.diagnode-3.com), which is actively recruiting newly diagnosed 12-28 yr. olds with type 1 diabetes at 60 sites in both the US and Europe. https://www.diamyd.com
Website
Categories
Pharmaceuticals
Phone
3017178865
Address
Kungsgatan 29
Stockholm, SE-111 56
Sweden
Stockholm, SE-111 56
Sweden